Insider Selling: ASP Isotopes (NASDAQ:ASPI) COO Sells $36,199.02 in Stock

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 8,438 shares of ASP Isotopes stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $4.29, for a total transaction of $36,199.02. Following the completion of the sale, the chief operating officer owned 2,248,441 shares in the company, valued at approximately $9,645,811.89. This trade represents a 0.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Robert Ainscow also recently made the following trade(s):

• On Wednesday, September 2nd, Robert Ainscow sold 25,000 shares of ASP Isotopes stock. The stock was sold at an average price of $3.90, for a total transaction of $97,500.00.

ASP Isotopes Price Performance

ASPI opened at $3.31 on Monday. The company has a market cap of $507.46 million, a PE ratio of -2.51 and a beta of 3.59. ASP Isotopes Inc. has a twelve month low of $3.30 and a twelve month high of $14.49. The company has a 50-day moving average price of $4.16 and a 200 day moving average price of $5.14. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.11). ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.The firm had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of ASP Isotopes by 9.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company’s stock valued at $148,000 after purchasing an additional 2,709 shares in the last quarter. Rhumbline Advisers lifted its position in ASP Isotopes by 20.9% during the second quarter. Rhumbline Advisers now owns 78,994 shares of the company’s stock worth $581,000 after buying an additional 13,668 shares in the last quarter. XTX Topco Ltd acquired a new position in ASP Isotopes during the second quarter worth $178,000. New York State Common Retirement Fund grew its holdings in ASP Isotopes by 418.2% in the 2nd quarter. New York State Common Retirement Fund now owns 17,100 shares of the company’s stock valued at $126,000 after buying an additional 13,800 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in ASP Isotopes by 2,205.0% in the 2nd quarter. Invesco Ltd. now owns 471,219 shares of the company’s stock valued at $3,468,000 after buying an additional 450,776 shares in the last quarter. 16.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ASPI has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Wall Street Zen raised shares of ASP Isotopes from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, ASP Isotopes has a consensus rating of “Hold” and a consensus price target of $13.00.

About ASP Isotopes

ASP Isotopes Inc (NASDAQ: ASPI) is a development-stage company focused on isotope enrichment and related technologies. The company is developing an isotope-separation platform known as the Aerodynamic Separation Process, which is intended to enrich selected chemical elements and isotopes for use in several specialized markets.

ASP Isotopes has identified applications in the nuclear energy, medical, semiconductor, and quantum-computing industries. Its development programs have included uranium enrichment as well as the production of specialty isotopes such as carbon-14, molybdenum-100, and silicon-28.